SAN DIEGO, July 29 /PRNewswire-FirstCall/ —
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the
treatment of obesity, will announce its second quarter ended June 30, 2010 financial results on Thursday, August 5, 2010 after the markets
close. The announcement will be followed by a live webcast and
conference call at 5:00 p.m. Eastern
time.
Orexigen management will host the call and webcast to discuss
financial results and recent business highlights. The live call may
be accessed by phone by calling (800) 901-5248 (domestic) or (617)
786-4512 (international), participant code 86709407. The webcast
can be accessed live on the investor relations section of the
Orexigen web site at www.orexigen.com and will
be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company
focused on the treatment of obesity. The Company has filed an NDA
with the FDA for its lead investigational product, Contrave®.
The Company’s second product, Empatic™, has completed Phase 2
clinical development. Each product candidate is designed to
act on a specific group of neurons in the central nervous system
with the goal of achieving appetite suppression and sustained
weight loss, through combination therapeutic approaches. Further
information about the Company can be found at ‘/>”/>
SOURCE
